PMID- 36192106
OWN - NLM
STAT- MEDLINE
DCOM- 20221005
LR  - 20221011
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 12
IP  - 10
DP  - 2022 Oct 3
TI  - Cross-sectional association between prolactin levels and non-alcoholic fatty 
      liver disease in patients with type 2 diabetes mellitus: a retrospective analysis 
      of patients from a single hospital in China.
PG  - e062252
LID - 10.1136/bmjopen-2022-062252 [doi]
LID - e062252
AB  - OBJECTIVE: This study aimed to retrospectively assess the association between 
      prolactin (PRL) and non-alcoholic fatty liver disease (NAFLD) in patients with 
      type 2 diabetes mellitus (T2DM). DESIGN AND SETTING: A retrospective, 
      cross-sectional study was conducted at a single hospital in Anhui, China. 
      PARTICIPANTS: A total of 406 patients with T2DM (230 men and 176 women) was 
      included. OUTCOME MEASURES: P values for the independent t-test, the Mann-Whitney 
      rank-sum test, the Spearman correlation analysis and multiple logistic regression 
      models were used to explore the association between PRL and NAFLD in patients 
      with T2DM. RESULTS: The results indicated that in both men and women, the levels 
      of PRL were significantly lower in the T2DM with NAFLD group than in the T2DM 
      without NAFLD group (men: 9.56 ng/mL vs 10.36 ng/mL, women: 10.38 ng/mL vs 
      12.97 ng/mL). In male patients, the levels of PRL were negatively correlated with 
      hip circumference (r=-0.141, p=0.032), homoeostasis model assessment for insulin 
      resistance (C-peptide) (r=-0.141, p=0.032) and triglyceride (TG) (r=-0.252, 
      p=0.000) values and inversely correlated with high-density lipoprotein (r=0.147, 
      p=0.025) levels. In female patients, PRL levels were negatively related to body 
      mass index (r=-0.192, p=0.011), diastolic blood pressure (r=-0.220, p=0.003), 
      waist circumference (r=-0.152, p=0.044), hip circumference (r=-0.157, p=0.037) 
      and TG (r=-0.258, p=0.001) values. Logistic regression analysis revealed a 
      negative relationship between PRL and NAFLD (men: OR 0.891, 95% CI 0.803 to 
      0.989, p=0.031; women: OR 0.874, 95% CI 0.797 to 0.957, p=0.004). As PRL levels 
      increased, NAFLD prevalence decreased in both sexes (men: p=0.012, women: 
      p=0.013). CONCLUSION: Our results suggest that low levels of PRL in the 
      physiological range were markers of NAFLD in patients with T2DM and that PRL 
      within the biologically high range may play a protective role in the pathogenesis 
      of NAFLD.
CI  - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Yuanyuan
AU  - Zhang Y
AUID- ORCID: 0000-0002-9369-2215
AD  - Department of Endocrinology, The First Affiliated Hospital of Anhui University of 
      Traditional Chinese Medicine, Hefei, Anhui, China.
FAU - Liu, Huaizhen
AU  - Liu H
AD  - Department of Endocrinology, The First Affiliated Hospital of Anhui University of 
      Traditional Chinese Medicine, Hefei, Anhui, China inkslab@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221003
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (C-Peptide)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Triglycerides)
RN  - 9002-62-4 (Prolactin)
SB  - IM
MH  - C-Peptide
MH  - China/epidemiology
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - Lipoproteins, HDL
MH  - Male
MH  - *Non-alcoholic Fatty Liver Disease
MH  - Prolactin
MH  - Retrospective Studies
MH  - Triglycerides
PMC - PMC9535252
OTO - NOTNLM
OT  - diabetes & endocrinology
OT  - general diabetes
OT  - general endocrinology
COIS- Competing interests: None declared.
EDAT- 2022/10/04 06:00
MHDA- 2022/10/06 06:00
PMCR- 2022/10/03
CRDT- 2022/10/03 21:05
PHST- 2022/10/03 21:05 [entrez]
PHST- 2022/10/04 06:00 [pubmed]
PHST- 2022/10/06 06:00 [medline]
PHST- 2022/10/03 00:00 [pmc-release]
AID - bmjopen-2022-062252 [pii]
AID - 10.1136/bmjopen-2022-062252 [doi]
PST - epublish
SO  - BMJ Open. 2022 Oct 3;12(10):e062252. doi: 10.1136/bmjopen-2022-062252.